VHL and neoplasm: In 2013, the laboratory of J. T. Hines designed a PROTAC based on the VHL peptide ligand and demonstrated for the first time that a PROTAC preferentially inhibited ovarian cancer cell proliferation and tumor growth in a mouse model without significant adverse effects on animal health [15].